These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 35106397)

  • 1. Role of Ketamine in the Treatment of Psychiatric Disorders.
    Derakhshanian S; Zhou M; Rath A; Barlow R; Bertrand S; DeGraw C; Lee C; Hasoon J; Kaye AD
    Health Psychol Res; 2021; 9(1):25091. PubMed ID: 35106397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.
    Kumari S; Chaudhry HA; Sagot A; Doumas S; Abdullah H; Alcera E; Solhkhah R; Afzal S
    Cureus; 2024 Feb; 16(2):e53987. PubMed ID: 38476783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamatergic Modulators for Major Depression from Theory to Clinical Use.
    McIntyre RS; Jain R
    CNS Drugs; 2024 Nov; 38(11):869-890. PubMed ID: 39150594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ketamine for Treatment-Resistant Mood Disorders.
    Park LT; Falodun TB; Zarate CA
    Focus (Am Psychiatr Publ); 2019 Jan; 17(1):8-12. PubMed ID: 31975953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.
    Kritzer MD; Mischel NA; Young JR; Lai CS; Masand PS; Szabo ST; Mathew SJ
    Ann Clin Psychiatry; 2022 Feb; 34(1):33-43. PubMed ID: 35166663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
    Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
    World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
    De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
    Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD).
    Olivier B; Olivier JDA
    Adv Exp Med Biol; 2024; 1456():49-66. PubMed ID: 39261423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial.
    Knyahnytska Y; Zomorrodi R; Kaster T; Voineskos D; Trevizol A; Blumberger D
    JMIR Res Protoc; 2022 Jan; 11(1):e30163. PubMed ID: 34882570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review.
    Boudieu L; Mennetrier M; Llorca PM; Samalin L
    Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review on Ketamine and Esketamine for Treatment-Resistant Depression and Suicidality in Adolescents: A New Hope?
    Pardossi S; Fagiolini A; Scheggi S; Cuomo A
    Children (Basel); 2024 Jun; 11(7):. PubMed ID: 39062250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Efficacy of Ketamine for Treatment-resistant Depression.
    Bratsos S; Saleh SN
    Cureus; 2019 Jul; 11(7):e5189. PubMed ID: 31565597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression.
    Cook J; Halaris A
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Dec; 119():110603. PubMed ID: 35842074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neural correlates of treatment response to ketamine for treatment-resistant depression: A systematic review of MRI-based studies.
    Yun JY; Kim YK
    Psychiatry Res; 2024 Oct; 340():116092. PubMed ID: 39116687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
    Sukhram SD; Yilmaz G; Gu J
    Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression.
    Liester M; Wilkenson R; Patterson B; Liang B
    Cureus; 2024 Apr; 16(4):e57654. PubMed ID: 38707115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive Intranasal Esketamine for Comorbid Treatment-Resistant Depression with Suicidal Ideation in Patients Receiving Palliative Care at a Comprehensive Cancer Center: A Case Series.
    Tomy M; Alexander W; Gupta S; Schaefer D; Case AA
    J Palliat Med; 2024 Aug; ():. PubMed ID: 39112018
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.